PharmaLundensis AB (XSAT:PHAL) Cyclically Adjusted FCF per Share: kr-0.19 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSAT:PHAL PharmaLundensis AB XSAT:PHAL
25 GF Score
Price kr0.32
! 1 Warning Sign
View Full Analysis

What is PharmaLundensis AB Cyclically Adjusted FCF per Share?

PharmaLundensis AB XSAT:PHAL 25 Cyclically Adjusted FCF per Share is kr-0.19 as of Mar. 2026. GuruFocus rates XSAT:PHAL with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

PharmaLundensis AB's adjusted free cash flow per share for the three months ended in Mar. 2026 was kr-0.017. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is kr-0.19 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-07-22), PharmaLundensis AB's current stock price is kr0.317. PharmaLundensis AB's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was kr-0.19. PharmaLundensis AB's Cyclically Adjusted Price-to-FCF of today is .


PharmaLundensis AB  (XSAT:PHAL) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


PharmaLundensis AB Cyclically Adjusted FCF per Share Related Terms


PharmaLundensis AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for PharmaLundensis AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaLundensis AB Cyclically Adjusted FCF per Share Chart

PharmaLundensis AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 -0.27 -0.23 -0.20

PharmaLundensis AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.22 -0.22 -0.20 -0.20 -0.19

XSAT:PHAL vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, PharmaLundensis AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaLundensis AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaLundensis AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where PharmaLundensis AB's Cyclically Adjusted Price-to-FCF falls into.


XSAT:PHAL
25GF Score
PharmaLundensis AB XSAT:PHAL
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaLundensis AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PharmaLundensis AB's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.017/133.5600*133.5600
=-0.017

Current CPI (Mar. 2026) = 133.5600.

PharmaLundensis AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.105 101.019 -0.139
201609 -0.075 101.138 -0.099
201612 0.000 102.022 0.000
201703 -0.055 102.022 -0.072
201706 -0.131 102.752 -0.170
201709 -0.087 103.279 -0.113
201712 0.000 103.793 0.000
201803 -0.058 103.962 -0.075
201806 -0.050 104.875 -0.064
201809 -0.077 105.679 -0.097
201812 0.000 105.912 0.000
201903 -0.044 105.886 -0.055
201906 -0.080 106.742 -0.100
201909 -0.037 107.214 -0.046
201912 0.000 107.766 0.000
202003 -0.049 106.563 -0.061
202006 -0.067 107.498 -0.083
202009 0.011 107.635 0.014
202012 0.000 108.296 0.000
202103 -0.017 108.360 -0.021
202106 -0.034 108.928 -0.042
202109 -0.026 110.338 -0.031
202112 0.000 112.486 0.000
202203 -0.024 114.825 -0.028
202206 -0.006 118.384 -0.007
202209 -0.036 122.296 -0.039
202212 0.000 126.365 0.000
202303 -0.006 127.042 -0.006
202306 -0.036 129.407 -0.037
202309 -0.037 130.224 -0.038
202312 -0.031 131.912 -0.031
202403 -0.022 132.205 -0.022
202406 0.057 132.716 0.057
202409 -0.027 132.304 -0.027
202412 -0.037 132.987 -0.037
202503 -0.017 132.825 -0.017
202506 -0.047 133.699 -0.047
202509 -0.027 133.480 -0.027
202512 -0.025 133.390 -0.025
202603 -0.017 133.560 -0.017

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of kr-0.19 mean?
PharmaLundensis AB (XSAT:PHAL) has a Cyclically Adjusted FCF per Share of kr-0.19 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on PharmaLundensis AB and its competitors.
Is PharmaLundensis AB's Cyclically Adjusted FCF per Share too high?
PharmaLundensis AB's current Cyclically Adjusted FCF per Share is kr-0.19. Overall, PharmaLundensis AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does PharmaLundensis AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
PharmaLundensis AB's Cyclically Adjusted FCF per Share of kr-0.19 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on PharmaLundensis AB and its competitors. PharmaLundensis AB's current Cyclically Adjusted FCF per Share is kr-0.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaLundensis AB stock overvalued right now?
PharmaLundensis AB (XSAT:PHAL) has a current Cyclically Adjusted FCF per Share of kr-0.19. The current Cyclically Adjusted FCF per Share is kr-0.19. PharmaLundensis AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For PharmaLundensis AB (XSAT:PHAL), the current Cyclically Adjusted FCF per Share is kr-0.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaLundensis AB Business Description

Address PharmaLundensis AB, Scheelevagen 2, Lund, SWE, 223 63
PharmaLundensis AB is a Sweden based drug manufacturing company, The company focuses on the development and marketing of pharmaceuticals. It is engaged in developing drugs for the lung diseases, such as chronic obstructive pulmonary disease and asthma, as well as drugs for mercury toxicology.
25GF Score

Get the complete analysis for XSAT:PHAL

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.32
Price